Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Background and objective Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used as adjunctive therapy to lifestyle intervention and metformin treatment in type 2 diabetes mellitus patients, as most GLP-1RAs have cardiovascular benefits; however, a number of adverse events (AEs) have been reported in postmarketing surveillance. Objective The aim of this study was to describe the AEs associated with GLP-1RA monotherapy and identify important medical event (IME) signals for GLP-1RAs. Methods Data from 1 April 2005 to 31 December 2021 from the US FDA Adverse Event Reporting System (FAERS) database were extracted to conduct disproportionality analysis and Bayesian analysis. AEs and IMEs were classified by system organ classes (SOCs) and preferred terms (PTs) according to the Medical Dictionary for Regulatory Activities (MedDRA ® ). The reporting odds ratio (ROR) and information component (IC) were used to indicate the disproportionality. Results A total of 71,515 records involving GLP-1RA monotherapy were submitted to the database, of which 16,350 records were GLP-1RA/IME pairs. Significant disproportionality emerged in five SOCs: 'gastrointestinal disorders' (n = 13,104; lower end of the 95% confidence interval (CI) of the IC [IC 025 ] = 1.34), 'investigations' (n = 6889; IC 025 = 0.64), 'metabolism and nutrition disorders' (n = 2943; IC 025 = 0.44), 'neoplasms benign/malignant' (n = 1989; IC 025 = 0.01), and 'hepatobiliary disorders' (n = 1497; IC 025 = 0.38). The most co…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, these databases reflect nonsubstantiated events reported by individuals and attributed—by those individuals—to a particular drug.61–63 They do not establish a causal or even an association relationship between a drug and the event, serving instead for hypothesis generation and prompt for future investigation of disproportional increased reporting of events.”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [63]
In the citing paper
“When classified by system organ classes, there was increased reporting of neoplasms (benign/malignant), including increased reporting of MTC and PTCs.63”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [63]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“In addition, emerging case reports have raised awareness of pancreatic cancer, which may potentially be a fatal complication associated with GLP-1RAs; however, such a connection is also disputed and controversial [14, 15].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 5×
“Furthermore, liraglutide and semaglutide were reported to be associated with a higher rate of diabetic retinopathy complications [11, 13].”
BackgroundResultInfluentialInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“As one of new antidiabetic therapies, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used as an adjunctive therapy to lifestyle intervention and metformin treatment [2].”
BackgroundLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 3×
“However, in randomized, double-blind, placebo-controlled trials, exenatide and lixisenatide have not demonstrated their effect in reducing major adverse cardiovascular events (MACEs) [4, 5].”
BackgroundEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · cited 2×
“However, in randomized, double-blind, placebo-controlled trials, exenatide and lixisenatide have not demonstrated their effect in reducing major adverse cardiovascular events (MACEs) [4, 5].”
BackgroundA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 2×
“conducted a 72-week, phase II trial involving patients with nonalcoholic steatohepatitis, and the results showed a significant improvement in fibrosis stage in the semaglutide group [44].”
Methodvan Puijenbroek, E. P., Bate, A., Leufkens, H. G. M., Lindquist, M., Orre, R., & Egberts, A. C. G. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.668 · Cited by 1,372 · cited 2×
“Significant disproportionality was considered to be present if ROR025 was >1 and IC025 was >0 [23], with the number of cases higher than 4.”
BackgroundPancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors
Klein, A. P. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00457-x · Cited by 1,258 · cited 2×
“Our findings revealed that GLP-1RAs showed an increased risk of pancreatic cancer, which remains a leading cause of death from cancer worldwide [35].”
BackgroundLiraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 3×
“GLP-1RAs are contraindicated in patients with a personal or family history of certain types of thyroid cancer, specifically thyroid C-cell tumors, owing to the evidence from animal studies that suggested GLP-1RA caused dose-dependent and treatment duration-dependent thyroid C-cell tumors [12]; however, it is still unc…”
BackgroundResultImpact of diabetes on cardiovascular disease: an update
Matheus, A. S. D. M., Tannus, L. R. M., Cobas, R. A., Palma, C. C. S., Negrato, C. A., & Gomes, M. D. B. (2013) · International Journal of Hypertension · doi:10.1155/2013/653789 · Cited by 547 · cited 1×
“Globally, type 2 diabetes mellitus (T2DM) is the dominant type of diabetes, and the subsequent cardiovascular complications are the leading cause of morbidity and mortality [1].”
BackgroundSingh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467 · cited 1×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299 · cited 3×
“Nausea, vomiting, diarrhea, and other gastrointestinal disorders are the most common AEs of GLP-1RAs, which can be explained by the drugs’ inherent mechanism of slowing gastric emptying [6].”
BackgroundA Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296
Harrison, S. A., Gawrieh, S., Roberts, K., Lisanti, C. J., Schwope, R. B., Cebe, K. M., Paradis, V., Bedossa, P., Aldridge Whitehead, J. M., Labourdette, A., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.034 · Cited by 293 · cited 2×
“in the Western world, in parallel with increasing risk of nonalcoholic steatohepatitis and even hepatocellular carcinoma, with the common features of abnormal liver function or fibrosis [39].”
BackgroundMonami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12926 · Cited by 243 · cited 3×
“In addition, emerging case reports have raised awareness of pancreatic cancer, which may potentially be a fatal complication associated with GLP-1RAs; however, such a connection is also disputed and controversial [14, 15].”
BackgroundYu, R. J., Krantz, M. S., Phillips, E. J., & Stone, C. A. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.09.021 · Cited by 222 · cited 1×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
Diets and drugs for weight loss and health in obesity – An update
Aaseth, J., Ellefsen, S., Alehagen, U., Sundfør, T. M., & Alexander, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111789 · Cited by 174 · cited 1×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
Hepatotoxicity of statins and other lipid‐lowering agents
Björnsson, E. S. (2017) · Liver International · doi:10.1111/liv.13308 · Cited by 173 · cited 2×
“Subsequently, we explored whether the concomitant medication had a potential effect on this risk, with the results showing that only one patient received semaglutide coadministered with atorvastatin calcium, which may be capable of inducing hepatotoxicity [24].”
BackgroundStorgaard, H., Cold, F., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12885 · Cited by 155 · cited 2×
“High levels of lipase or amylase and gastrointestinal reactions, which were often observed with GLP-1RA therapy, were also the common symptoms of acute pancreatitis; thus, in some cases it is difficult to identify the reactions caused by acute pancreatitis or AEs of GLP-1RAs [34].”
BackgroundPancreatic Cancer Following Acute Pancreatitis: A Population-based Matched Cohort Study
Sadr‐Azodi, O., Oskarsson, V., Discacciati, A., Videhult, P., Askling, J., & Ekbom, A. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0255-9 · Cited by 133 · cited 2×
“In a large population-based cohort study, it has been shown that patients with a diagnosis of acute pancreatitis had higher risks of pancreatic cancer during the first 2 years when compared with the matched general population [36].”
BackgroundHonigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1966 · Cited by 127 · cited 2×
“albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide, of which albiglutide, dulaglutide, liraglutide, and semaglutide have been reported to produce favorable cardiovascular outcomes in randomized, double-blind, placebo-controlled trials [3].”
BackgroundHarnessing big data to characterize immune-related adverse events
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125 · cited 1×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
Shi, J. R., Deng, Q., Wan, C., Zheng, M., Huang, F., & Tang, B. (2017) · Chemical Science · doi:10.1039/c7sc02189e · Cited by 99 · cited 2×
“In addition, it is well-known that pancreatic amylase and lipase are essential biomarkers of acute pancreatitis [33].”
BackgroundReporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019
Setyawan, J., Azimi, N. A., Strand, V., Yarur, A. J., & Fridman, M. (2021) · Drug Safety · doi:10.1007/s40264-021-01082-y · Cited by 88 · cited 2×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
MethodIncretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study
Faillie, J.-L., Azoulay, L., Patenaude, V., Hillaire-Buys, D., & Suissa, S. (2014) · BMJ · doi:10.1136/bmj.g2780 · Cited by 83 · cited 1×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
Wenten, M., Gaebler, J. A., Hussein, M., Pelletier, E. M., Smith, D. B., Girase, P., Noel, R. A., Braun, D. K., & Bloomgren, G. L. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03652.x · Cited by 75 · cited 2×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
BackgroundChen, C., Chen, T., Liang, J., Guo, X., Xu, J., Zheng, Y., Guo, Z., Chi, L., Wei, L., Chen, X., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.616505 · Cited by 63
Cusi, K. (2019) · Hepatology · doi:10.1002/hep.30670 · Cited by 52
Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
Zhou, X., Ye, X., Guo, X., Liu, D., Xu, J., Hu, F., Zhai, Y., Gao, Y., Xu, X., Dong, Z., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.766125 · Cited by 49 · cited 2×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
MethodImpact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis
Kalavalapalli, S., Bril, F., Guingab, J., Vergara, A., Garrett, T. J., Sunny, N. E., & Cusi, K. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0007 · Cited by 48 · cited 2×
“Although hepatocytes lack GLP-1 receptors [40], GLP-1RAs have presented significant benefits in relation to liver enzymes, metabolic disorder, and insulin resistance by multiple indirect pathways [41–43].”
BackgroundChan, W., Tan, S., Chan, S., Lee, Y., Tee, H., Mahadeva, S., Goh, K., Ramli, A. S., Mustapha, F., Kosai, N. R., et al. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15787 · Cited by 46 · cited 1×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice
Ellenbroek, J. H., Töns, H. A. M., Westerouen van Meeteren, M. J. A., de Graaf, N., Hanegraaf, M. A., Rabelink, T. J., Carlotti, F., & de Koning, E. J. P. (2013) · Diabetologia · doi:10.1007/s00125-013-2957-2 · Cited by 43 · cited 2×
“The studies conducted on rodents suggested GLP-1RAs might have the capability of triggering acute pancreatitis, and ultimately increased the risk of pancreatic cancer [28, 29].”
BackgroundYang, Z., Yu, M., Mei, M., Chen, C., Lv, Y., Xiang, L., & Li, R. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.10.003 · Cited by 37 · cited 3×
“In a previous pharmacovigilance study, the combination therapies with GLP-1RAs and insulin had a higher DKA risk [27].”
BackgroundResultBarriers and Solutions for Prescribing Obesity Pharmacotherapy
Fujioka, K., & Harris, S. R. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.02.007 · Cited by 28 · cited 1×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
GLP-1R agonists for the treatment of obesity: a patent review (2015-present)
Liu, C., Zou, Y., & Qian, H. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1811851 · Cited by 28 · cited 1×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
Yang, R., Yin, N., Zhao, Y. J., Li, D., Zhang, X., Li, X., Zhang, Y., & Faiola, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.772768 · Cited by 26 · cited 1×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
Self-citationLiao, X., Liu, Z., & Hong-tao, S. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13472 · Cited by 18 · cited 1×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
Papazafiropoulou, A. K., Melidonis, A. J., & Antonopoulos, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200909142126 · Cited by 16
Katsuhara, Y., & Ikeda, S. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01006-9 · Cited by 16 · cited 1×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
Soranna, D., Bosetti, C., Casula, M., Tragni, E., Catapano, A. L., Vecchia, C. L., Merlino, L. G., & Corrao, G. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.02.013 · Cited by 13 · cited 1×
“42) Onset time, days (median [IQR])a 45 [3-197] 79 [16-277]”
Cited by
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
Self-citationMin, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61
Self-citationStefanou, M.-I., Theodorou, A., Malhotra, K., Aguiar de Sousa, D., Katan, M., Palaiodimou, L., Katsanos, A. H., Koutroulou, I., Lambadiari, V., Lemmens, R., et al. (2024) · European Stroke Journal · doi:10.1177/23969873241234238 · Cited by 60
“…our group 13 and others (summarized in Supplemental Table S1), 14–20 as well as data from real-world observational and pharmacovigilance studies, 43,44 that have established the robust cardiovascular and cerebrovascular benefits from GLP-1RAs in T2DM and laid the ground for their broader…”
Alenzi, K. A. O., Alsuhaibani, D. S., Batarfi, B. S., & Alshammari, T. M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364110 · Cited by 52
Metadata
- Authors
- Wu, T., Zhang, Y., Shi, Y., Yu, K., Zhao, M., Liu, S., & Zhao, Z.
- Affiliations
- Capital Medical University (CN)
- Peking University People's Hospital (CN)
- Tianjin University of Traditional Chinese Medicine (CN)
- Corresponding author
- Zhang, Yang
- Zhao, Zhigang
- Venue
- Clinical Drug Investigation
- Published
- 2022-09-30
- Volume
- 42
- Issue
- 11
- Pages
- 965-975
- ISSN
- 0114-2402 (ISSN-L)
- 1173-2563
- 1179-1918
- OpenAlex
- W4298088938
- Semantic Scholar
- 14b473e21939c943914e6e2caef902735f699fd7
- Cited by
- 38
- References
- 41
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 15 · 2023: 2
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Clinical Drug Investigation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, adverse drug reactions, type 2 diabetes, drug safety, post-marketing surveillance, disproportionality analysis, drug-induced liver injury, renal cell carcinoma, kidney stones, pancreatitis, osteomyelitis, ileus, drug-induced nephrolithiasis, drug-induced pancreatitis, drug-induced gastrointestinal disorders, drug-induced nausea
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Bayes Theorem, Diabetes Mellitus, Type 2, Humans, Neoplasms, United States, United States Food and Drug Administration, Databases, Factual, Pharmacovigilance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.